However, it should be noted that the effectiveness of sunitinib is impeded by elevated levels of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment, which are induced by both tumor burden and the administration of EZH2 inhibitors [93, 94]. This evidence concerns the gene EZH2 and neoplasm.